6.4557
price up icon2.87%   0.1757
 
loading
전일 마감가:
$6.28
열려 있는:
$6.28
하루 거래량:
284.69K
Relative Volume:
0.36
시가총액:
$229.75M
수익:
-
순이익/손실:
$-144.01M
주가수익비율:
-1.9445
EPS:
-3.32
순현금흐름:
$-113.02M
1주 성능:
-9.14%
1개월 성능:
-42.53%
6개월 성능:
-44.21%
1년 성능:
-35.01%
1일 변동 폭
Value
$6.0919
$6.50
1주일 범위
Value
$6.04
$7.11
52주 변동 폭
Value
$3.61
$22.74

바이오미아 퓨전 Stock (BMEA) Company Profile

Name
명칭
Biomea Fusion Inc
Name
전화
(650) 980-9099
Name
주소
900 MIDDLEFIELD ROAD, REDWOOD CITY
Name
직원
107
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
BMEA's Discussions on Twitter

BMEA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
BMEA 6.44 229.75M 0 -144.01M -113.02M -3.32
VRTX 450.61 115.43B 10.63B -479.80M -1.35B 13.33
REGN 749.05 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 589.59 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 247.41 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 106.82 24.89B 3.30B -501.07M 1.03B 11.54

바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-10-09 개시 Edward Jones Buy
2024-09-27 업그레이드 Rodman & Renshaw Neutral → Buy
2024-09-27 업그레이드 Truist Hold → Buy
2024-08-29 개시 CapitalOne Overweight
2024-06-11 다운그레이드 Truist Buy → Hold
2024-06-07 다운그레이드 Barclays Overweight → Equal Weight
2024-04-02 다운그레이드 JP Morgan Overweight → Neutral
2024-02-06 개시 Truist Buy
2023-07-27 개시 Scotiabank Sector Outperform
2023-06-26 다운그레이드 Jefferies Buy → Hold
2023-05-12 개시 Barclays Overweight
2023-03-29 재확인 Oppenheimer Outperform
2023-03-28 재확인 H.C. Wainwright Buy
2023-02-24 개시 Citigroup Buy
2022-06-02 재개 H.C. Wainwright Buy
2022-01-12 개시 H.C. Wainwright Buy
2021-12-17 개시 Oppenheimer Outperform
2021-05-11 개시 JP Morgan Overweight
2021-05-11 개시 Jefferies Buy
2021-05-11 개시 Piper Sandler Overweight
모두보기

바이오미아 퓨전 주식(BMEA)의 최신 뉴스

pulisher
08:14 AM

HC Wainwright Reiterates Buy Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat

08:14 AM
pulisher
Nov 18, 2024

Late-Breaker Oral Presentation Showing New Analysis from - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Biomea Fusion's Diabetes Drug Shows 1.23% HbA1c Drop in Key Patient Group | BMEA Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 17, 2024

(BMEA) Investment Report - Stock Traders Daily

Nov 17, 2024
pulisher
Nov 13, 2024

We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate - Yahoo Finance

Nov 13, 2024
pulisher
Nov 06, 2024

How To Trade (BMEA) - Stock Traders Daily

Nov 06, 2024
pulisher
Nov 05, 2024

Biomea Fusion, Inc. Reveals Preclinical Data on Icovamenib and BMF-650 in Recent SEC Filing - Defense World

Nov 05, 2024
pulisher
Nov 04, 2024

Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook - Investing.com India

Nov 04, 2024
pulisher
Nov 04, 2024

Biomea Fusion FY2024 EPS Estimate Raised by HC Wainwright - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

HC Wainwright Forecasts Increased Earnings for Biomea Fusion - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Biomea Fusion (NASDAQ:BMEA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World

Nov 04, 2024
pulisher
Nov 04, 2024

Biomea Fusion’s (BMEA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Nov 04, 2024
pulisher
Nov 02, 2024

BMEABiomea Fusion, Inc. Latest Stock News & Market Updates - StockTitan

Nov 02, 2024
pulisher
Nov 01, 2024

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 01, 2024
pulisher
Nov 01, 2024

Biomea Fusion stock PT raised by Piper Sandler, citing pipeline potential - Investing.com Australia

Nov 01, 2024
pulisher
Oct 31, 2024

HC Wainwright Reiterates "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Biomea Fusion Unveils Promising Diabetes Treatment Innovations - TipRanks

Oct 31, 2024
pulisher
Oct 30, 2024

Biomea Fusion Reports Q3 2024 Financial Results - MSN

Oct 30, 2024
pulisher
Oct 30, 2024

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate - GlobeNewswire

Oct 30, 2024
pulisher
Oct 30, 2024

Barclays Forecasts Strong Price Appreciation for Biomea Fusion (NASDAQ:BMEA) Stock - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Biomea Awaits 2 Data Readouts Of Diabetes StudiesCan The Stock Get Its Mojo Back? - RTTNews

Oct 30, 2024
pulisher
Oct 30, 2024

Biomea Fusion (NASDAQ:BMEA) Announces Earnings Results - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Biomea Fusion price target raised to $11 from $9 at Barclays - TipRanks

Oct 30, 2024
pulisher
Oct 29, 2024

Biomea Fusion reports Q3 EPS (91c), consensus (95c) - TipRanks

Oct 29, 2024
pulisher
Oct 29, 2024

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights - The Manila Times

Oct 29, 2024
pulisher
Oct 28, 2024

Biomea Fusion options imply 6.1% move in share price post-earnings - TipRanks

Oct 28, 2024
pulisher
Oct 28, 2024

Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Buy" by Brokerages - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Oct 28, 2024
pulisher
Oct 27, 2024

(BMEA) Technical Data - Stock Traders Daily

Oct 27, 2024
pulisher
Oct 22, 2024

Biomea Fusion shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Australia

Oct 22, 2024
pulisher
Oct 22, 2024

Biomea Fusion's (BMEA) Buy Rating Reiterated at HC Wainwright - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Biomea Fusion shares maintain Buy rating from H.C. Wainwright - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Exchange Traded Concepts LLC Acquires 8,079 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World

Oct 22, 2024
pulisher
Oct 21, 2024

Biomea Fusion's icovamenib gets global and US naming approval - Investing.com India

Oct 21, 2024
pulisher
Oct 21, 2024

Biomea Fusion's icovamenib gets global and US naming approval By Investing.com - Investing.com South Africa

Oct 21, 2024
pulisher
Oct 21, 2024

Biomea Fusion announces approval of ‘icovamenib’ as INN for BMF-219 - TipRanks

Oct 21, 2024
pulisher
Oct 21, 2024

Biomea Fusion Announces Approval of 'icovamenib” as International Nonproprietary Name for BMF-219 - The Manila Times

Oct 21, 2024
pulisher
Oct 21, 2024

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219 - GlobeNewswire

Oct 21, 2024
pulisher
Oct 19, 2024

Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World

Oct 19, 2024
pulisher
Oct 16, 2024

(BMEA) Investment Analysis and Advice - Stock Traders Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Griffin Asset Management Inc. Purchases 57,180 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-21 - The Manila Times

Oct 15, 2024
pulisher
Oct 13, 2024

Marshall Wace LLP Sells 3,900 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World

Oct 13, 2024
pulisher
Oct 13, 2024

Squarepoint Ops LLC Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat

Oct 13, 2024
pulisher
Oct 12, 2024

Investigation Launched into Biomea Fusion Securities - Bit Perfect Solutions

Oct 12, 2024

바이오미아 퓨전 (BMEA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
자본화:     |  볼륨(24시간):